The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
The biology of ovarian cancer: new opportunities for translation
Open accessAbstract
Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approximately 30%. Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome. Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the molecular and cellular levels to personalize individual strategies for treatment and to optimize early detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Induction of autophagy and inhibition of tumorigenesis by beclin 1
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B. (1999) · Nature · doi:10.1038/45257 · Cited by 3,347
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Self-citationSaam, J., Arnell, C., Theisen, A., Moyes, K., Marino, I., Roundy, K. M., & Wenstrup, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,526
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293
Regulation and Function of IKK and IKK-Related Kinases
Häcker, H., & Karin, M. (2006) · Science's STKE · doi:10.1126/stke.3572006re13 · Cited by 1,274
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
microRNAs exhibit high frequency genomic alterations in human cancer
Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M. S., Giannakakis, A., Liang, S., Naylor, T. L., Barchetti, A., Ward, M. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508889103 · Cited by 1,031
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Szotek, P. P., Pieretti-Vanmarcke, R., Masiakos, P. T., Dinulescu, D. M., Connolly, D., Foster, R., Dombkowski, D., Preffer, F., MacLaughlin, D. T., & Donahoe, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603672103 · Cited by 751
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 572
Ovarian carcinoma diagnosis: Results of a national ovarian cancer survey
Goff, B. A., Mandel, L., Muntz, H. G., & Melancon, C. H. (2000) · Cancer · doi:10.1002/1097-0142(20001115)89:10<2068::aid-cncr6>3.0.co;2-z · Cited by 502
Beyond chemotherapy: targeted therapies in ovarian cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2583 · Cited by 495
Stress hormone-mediated invasion of ovarian cancer cells
Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., Li, Y., Gershenson, D. M., Lutgendorf, S., & Cole, S. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1698 · Cited by 491
Alvero, A. B., Chen, R., Fu, H.-H., Montagna, M., Schwartz, P. E., Rutherford, T., Silasi, D.-A., Steffensen, K. D., Waldstrom, M., Visintin, I., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7533 · Cited by 489
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells
Lu, Z., Luo, R. Z., Lu, Y., Zhang, X., Yu, Q., Khare, S., Kondo, S., Kondo, Y., Yu, Y., Mills, G. B., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35512 · Cited by 466
Self-citationKurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440
Self-citationLin, Y. G., Kunnumakkara, A. B., Nair, A., Merritt, W. M., Han, L. Y., Armaiz-Pena, G. N., Kamat, A. A., Spannuth, W. A., Gershenson, D. M., Lutgendorf, S. K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3072 · Cited by 440
Schwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Gubbels, J. A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., Bera, T. K., Connor, J., Sathyanarayana, B. K., Lee, B., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-50 · Cited by 422
Kryczek, I., Lange, A., Mottram, P., Alvarez, X., Cheng, P., Hogan, M., Moons, L., Wei, S., Zou, L., Machelon, V., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.465.65.2 · Cited by 421
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Kojima, K., Konopleva, M., Samudio, I. J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407
Janot, F., de Raucourt, D., Benhamou, E., Ferron, C., Dolivet, G., Bensadoun, R.-J., Hamoir, M., Géry, B., Julieron, M., Castaing, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0102 · Cited by 405
The essential role of MEKK3 in TNF-induced NF-κB activation
Yang, J., Lin, Y., Guo, Z., Cheng, J., Huang, J., Deng, L., Liao, W., Chen, Z., Liu, Z.-G., & Su, B. (2001) · Nature Immunology · doi:10.1038/89769 · Cited by 396
Role of Vascular Endothelial Growth Factor in Ovarian Cancer
Mesiano, S., Ferrara, N., & Jaffe, R. B. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65669-6 · Cited by 392
Kulbe, H., Thompson, R., Wilson, J. L., Robinson, S., Hagemann, T., Fatah, R., Gould, D., Ayhan, A., & Balkwill, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2941 · Cited by 386
Aurora Kinases as Anticancer Drug Targets
Gautschi, O., Heighway, J., Mack, P. C., Purnell, P. R., Lara, P. N., & Gandara, D. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2179 · Cited by 386
Moynahan, M. E., Cui, T. Y., & Jasin, M. (2001) · PubMed · Cited by 382
Expression of Angiogenesis-Related Genes and Progression of Human Ovarian Carcinomas in Nude Mice
Yoneda, J., Kuniyasu, H., Price, J. E., Bucana, C. D., Fidler, I. J., & Crispens, M. A. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.6.447 · Cited by 375
(2008) · doi:10.1016/b978-1-4160-3703-3.x5001-7 · Cited by 373
Hu, L., Hofmann, J., Lu, Y., Mills, G. B., & Jaffe, R. B. (2002) · PubMed · Cited by 361
Self-citationBRCA2 mutations in primary breast and ovarian cancers
Lancaster, J. M., Wooster, R., Mangion, J., Phelan, C. M., Cochran, C., Gumbs, C., Seal, S., Barfoot, R., Collins, N., Bignell, G., et al. (1996) · Nature Genetics · doi:10.1038/ng0696-238 · Cited by 360
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
Precursor lesions of ovarian epithelial malignancy
Feeley, K. M., & Wells, M. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01042.x · Cited by 351
Yang, G., Rosen, D. G., Zhang, Z., Bast, R. C., Mills, G. B., Colacino, J. A., Mercado-Uribe, I., & Liu, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605752103 · Cited by 341
Self-citationChetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323
Marquez, R. T., Baggerly, K. A., Patterson, A. P., Liu, J., Broaddus, R., Frumovitz, M., Atkinson, E. N., Smith, D. I., Hartmann, L., Fishman, D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2509 · Cited by 308
Self-citationCheng, W., Liu, J., Yoshida, H., Rosen, D., & Naora, H. (2005) · Nature Medicine · doi:10.1038/nm1230 · Cited by 305
Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer
Curiel, T. J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M., Wei, S., Zou, L., Kryczek, I., Hoyle, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1272 · Cited by 297
Genetic analysis of benign, low-grade, and high-grade ovarian tumors.
Iwabuchi, H., Sakamoto, M., Sakunaga, H., Y, Y., Carcangiu, M. L., Pinkel, D., Yang‐Feng, T. L., & Gray, J. W. (1995) · PubMed · Cited by 292
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
Jazaeri, A. A., Yee, C. J., Sotiriou, C., Brantley, K. R., Boyd, J., & Liu, E. T. (2002) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/94.13.990 · Cited by 282
A Genetically Defined Model for Human Ovarian Cancer
Liu, J., Yang, G., Thompson-Lanza, J. A., Glassman, A., Hayes, K., Patterson, A., Marquez, R. T., Auersperg, N., Yu, Y., Hahn, W. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3380 · Cited by 273
Self-citationInhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
Burke, W. M., Jin, X., Lin, H.-J., Huang, M., Liu, R., Reynolds, R. K., & Lin, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204990 · Cited by 269
Schilder, R. J., Sill, M. W., Chen, X., Darcy, K. M., Decesare, S. L., Lewandowski, G., Lee, R. B., Arciero, C. A., Wu, H., & Godwin, A. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0462 · Cited by 258
Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites
Zebrowski, B. K., Liu, W., Ramirez, K., Akagi, Y., Mills, G. B., & Ellis, L. M. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0373-0 · Cited by 254
Self-citationVasey, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1562 · Cited by 245
Fishman, D. A., Stack, S., Ellerbroek, S. M., & Liu, Y. (2022) · PubMed · doi:10.7274/24738663 · Cited by 241
Eder, A. M., Sui, X., Rosen, D. G., Nolden, L. K., Cheng, K. W., Lahad, J. P., Kango-Singh, M., Lu, K. H., Warneke, C. L., Atkinson, E. N., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505641102 · Cited by 238
Self-citationGORDON, A. N., FINKLER, N., EDWARDS, R. P., GARCIA, A. A., CROZIER, M., IRWIN, D. H., & BARRETT, E. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00137.x · Cited by 221
Ren, J., Xiao, Y.-J., Singh, L. S., Zhao, X., Zhao, Z., Feng, L., Rose, T. M., Prestwich, G. D., & Xu, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1292 · Cited by 220
Kajiyama, H., Shibata, K., Terauchi, M., Ino, K., Nawa, A., & Kikkawa, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23083 · Cited by 220
Proteins with whey-acidic-protein motifs and cancer
Bouchard, D., Morisset, D., Bourbonnais, Y., & Tremblay, G. M. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70579-4 · Cited by 204
Emerging Role of RAB GTPases in Cancer and Human Disease
Cheng, K. W., Lahad, J. P., Gray, J. W., & Mills, G. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0573 · Cited by 203
Self-citationHeinemann, V., Stintzing, S., Kirchner, T., Boeck, S., & Jung, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.005 · Cited by 203
Genetic analysis of early- versus late-stage ovarian tumors.
Shridhar, V., Lee, J., Pandita, A., Iturria, S., Avula, R., Staub, J., Morrissey, M., Calhoun, E., Sen, A., Kalli, K., et al. (2001) · PubMed · Cited by 196
Self-citationLi, K., Li, Y., Wu, W., Gordon, W. R., Chang, D. W., Lu, M., Scoggin, S., Fu, T., Vien, L., Histen, G., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800170200 · Cited by 195
Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells
Fang, X., Yu, S., Bast, R. C., Liu, S., Xu, H.-J., Hu, S.-X., LaPushin, R., Claret, F. X., Aggarwal, B. B., Lu, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306662200 · Cited by 192
Self-citationThe p53 tumor suppressor gene frequently is altered in gynecologic cancers
Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., & Bast, R. C. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70414-7 · Cited by 184
Self-citationSpectrum of Mutation and Frequency of Allelic Deletion of the p53 Gene in Ovarian Cancer
Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke-Pearson, D. L., Soper, J. T., Bast, R. C., & Berchuck, A. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.18.1513 · Cited by 184
Self-citationHuman tissue kallikreins: The cancer biomarker family
Paliouras, M., Borgono, C., & Diamandis, E. P. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.018 · Cited by 183
Rubin, S. C., Blackwood, M. A., Bandera, C., Behbakht, K., Benjamin, I., Rebbeck, T. R., & Boyd, J. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)70476-4 · Cited by 179
Jiang, Y.-P., Wu, X.-H., Shi, B., Wu, W.-X., & Yin, G.-R. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.02.036 · Cited by 173
Feng, W., Marquez, R. T., Lu, Z., Liu, J., Lu, K. H., Issa, J. J., Fishman, D. M., Yu, Y., & Bast, R. C. (2008) · Cancer · doi:10.1002/cncr.23323 · Cited by 168
Self-citationStudy of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer
Madhusudan, S., Muthuramalingam, S. R., Braybrooke, J. P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F., & Ganesan, T. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.127 · Cited by 167
Birrer, M., Johnson, M. E., Hao, K., Wong, K. K., Park, D., Bell, A., Welch, W., Berkowitz, R., & Mok, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0795 · Cited by 165
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
Buller, R. E., Runnebaum, I. B., Karlan, B. Y., Horowitz, J. A., Shahin, M., Buekers, T., Petrauskas, S., Kreienberg, R., Slamon, D., & Pegram, M. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700472 · Cited by 164
Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer
Kamat, A. A., Kim, T. J., Landen, C. N., Lu, C., Han, L. Y., Lin, Y. G., Merritt, W. M., Thaker, P. H., Gershenson, D. M., Bischoff, F. Z., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3282 · Cited by 162
The epigenetics of ovarian cancer drug resistance and resensitization
Balch, C., Huang, T. H.-M., Brown, R., & Nephew, K. P. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.05.025 · Cited by 160
Havrilesky, L. J., Darcy, K. M., Hamdan, H. B., Priore, R. L., Leon, J., Bell, J., & Berchuck, A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.052 · Cited by 156
Monk, B. J., Han, E. S., Josephs-Cowan, C. A., Pugmire, G., & Burger, R. A. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.006 · Cited by 140
Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer
Landen, C. N., Lu, C., Han, L. Y., Coffman, K. T., Bruckheimer, E., Halder, J., Mangala, L. S., Merritt, W. M., Lin, Y. G., Gao, C., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj414 · Cited by 136
Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites.
Milliken, D., Scotton, C. J., Raju, S., Balkwill, F. R., & Wilson, J. L. (2002) · PubMed · Cited by 136
Proteoglycans in host–pathogen interactions: molecular mechanisms and therapeutic implications
Bartlett, A. H., & Park, P. W. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001367 · Cited by 135
Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium
Szlosarek, P. W., Grimshaw, M. J., Kulbe, H., Wilson, J. L., Wilbanks, G. D., Burke, F., & Balkwill, F. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0303 · Cited by 135
Rosen, D. G., Mercado‐Uribe, I., Yang, G. S., Bast, R. C., Amin, H. M., Lai, R. L., & Liu, J. (2006) · Cancer · doi:10.1002/cncr.22293 · Cited by 133
Self-citationUse of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
Rustin, G. J. S., Bast, R. C., Kelloff, G. J., Barrett, J. C., Carter, S. K., Nisen, P. D., Sigman, C. C., Parkinson, D. R., & Ruddon, R. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0787 · Cited by 133
Self-citationStröbel, T., Swanson, L., & Cannistra, S. A. (1997) · PubMed · Cited by 123
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
Numnum, T. M., Rocconi, R. P., Whitworth, J. M., & Barnes, M. N. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.018 · Cited by 123
EphA2 overexpression is associated with angiogenesis in ovarian cancer
Lin, Y. G., Han, L. Y., Kamat, A. A., Merritt, W. M., Landen, C. N., Deavers, M. T., Fletcher, M. S., Urbauer, D. L., Kinch, M. S., & Sood, A. K. (2006) · Cancer · doi:10.1002/cncr.22415 · Cited by 122
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer
Landen, C. N., Merritt, W. M., Mangala, L. S., Sanguino, A. M., Bucana, C. D., Lü, C., Lin, Y. G., Han, L. Y., Kamat, A. A., Schmandt, R. E., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.12.3468 · Cited by 119
Berchuck, A., Rodriguez, G., Olt, G. J., et al. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91697-9 · Cited by 111
A New Small-Molecule Stat3 Inhibitor
McMurray, J. S. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.11.001 · Cited by 106
Sunde, J. S., Donninger, H., Wu, K., Johnson, M. E., Pestell, R. G., Rose, G. S., Mok, S. C., Brady, J. N., Bonome, T., & Birrer, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0683 · Cited by 99
Early Detection of Ovarian Cancer
Das, P. M., & Bast, R. C. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.3.291 · Cited by 96
Self-citationSchuyer, M., van der Burg, M. E. L., Henzen-Logmans, S. C., Fieret, J. H., Klijn, J. G. M., Look, M. P., Foekens, J. A., Stoter, G., & Berns, E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2101 · Cited by 95
Barbolina, M. V., Adley, B. P., Ariztia, E. V., Liu, Y., & Stack, M. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608428200 · Cited by 93
Overexpression of MEKK3 Confers Resistance to Apoptosis through Activation of NFκB
Samanta, A. K., Huang, H. J., Bast, R. C., & Liao, W. S. ‐. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311659200 · Cited by 84
Self-citationExpression of the E2F Family of Transcription Factors and Its Clinical Relevance in Ovarian Cancer
Reimer, D., Sadr, S., Wiedemair, A., GOEBEL, G., Concin, N., Hofstetter, G., Marth, C., & Zeimet, A. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.073 · Cited by 77
Berchuck, A., Kohler, M. F., Hopkins, M. P., Humphrey, P. A., Robboy, S. J., Rodriguez, G. C., Soper, J. T., Clarke‐Pearson, D. L., & Bast, R. C. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1037 · Cited by 69
Self-citationImpact of vessel maturation on antiangiogenic therapy in ovarian cancer
Lü, C., Thaker, P. H., Lin, Y. G., Spannuth, W. A., Landen, C. N., Merritt, W. M., Jennings, N. B., Langley, R. R., Gershenson, D. M., Yancopoulos, G. D., et al. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.12.028 · Cited by 62
The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
Drew, Y., & Calvert, H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1414.020 · Cited by 61
Perineal talc use and ovarian cancer: a critical review
Muscat, J. E., & Huncharek, M. S. (2008) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e32811080ef · Cited by 58
Critical evaluation of p53 as a prognostic marker in ovarian cancer
Hall, J. A., Paul, J., & Brown, R. E. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399404007781 · Cited by 54
Targeted therapy for epithelial ovarian cancer: Current status and future prospects
See, H. T., Kavanagh, J. J., Hu, W., & Bast, R. C. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13601.x · Cited by 52
Self-citationLancaster, J. M., Sayer, R. A., Blanchette, C., Calingaert, B., Whitaker, R. S., Schildkraut, J., Marks, J. R., & Berchuck, A. (2003) · PubMed · Cited by 52
Murph, M. M., Tanaka, T., Liu, S., & Mills, G. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1721 · Cited by 51
Self-citationBRCA Mutation Frequency and Penetrance: New Data, Old Debate
Offit, K. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj500 · Cited by 48
Pieretti‐Vanmarcke, R., Donahoe, P. K., Pearsall, L. A., Dinulescu, D. M., Connolly, D. C., Halpern, E. F., Seiden, M. V., & MacLaughlin, D. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607959103 · Cited by 43
Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis
Cai, K. Q., Yang, W., Capo‐chichi, C. D., Vanderveer, L., Wu, H. G., Godwin, A. K., & Xu, X. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20273 · Cited by 40
Duan, Z., Bradner, J. E., Greenberg, E. F., Mazitschek, R., Foster, R., Mahoney, J., & Seiden, M. V. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.038117 · Cited by 39
Rodabaugh, K. J., Biggs, R. B., Qureshi, J. A., Barrett, A. J., Welch, W. R., Bell, D. A., Berkowitz, R. S., & Mok, S. C. (1995) · PubMed · Cited by 38
Significance of Fas receptor protein expression in epithelial ovarian cancer
REED, J., Hakam, A., Nicosia, S. V., & Coppola, D. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.06.015 · Cited by 15
Bast, R. C., Iyer, R. B., Hu, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3500 · Cited by 14
Self-citationMolecular Pathogenesis of Epithelial Ovarian Cancer
Bast, R. C., & Mills, G. B. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10034-2 · Cited by 3
Self-citation
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,905
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Repair Pathway Choices and Consequences at the Double-Strand Break
Ceccaldi, R., Rondinelli, B., & D’Andrea, A. D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.07.009 · Cited by 1,499
Mucins in cancer: function, prognosis and therapy
Kufe, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2761 · Cited by 1,396
Metadata
- Authors
- Bast, R. C., Hennessy, B., & Mills, G. B.
- Venue
- Nature Reviews Cancer
- Published
- 2009-06
- Volume
- 9
- Issue
- 6
- Pages
- 415-428
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2090968329
- Cited by
- 1,358
- References
- 117
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.